Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma
Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study aims to observe the therapeutic effect of leukotriene modulator montelukast alone
or combined with inhaled corticosteroid(ICS) on cough variant asthma(CVA).
The investigators hypothesize:
1. Cough score and cough reflex sensitivity will be improved after treatment with
montelukast, inhaled corticosteroid/β2 agonist(ICS/LABA), and two combinations.
2. Combination of leukotriene modulator and inhaled corticosteroid/β2 agonist may have
better efficacy when compared to montelukast, corticosteroid/β2 agonist alone while MON,
is comparable to symbicort.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Budesonide, Formoterol Fumarate Drug Combination Montelukast